LivaNova’s (LIVN) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of LivaNova (NASDAQ:LIVN) in a report issued on Tuesday morning,Benzinga reports. The brokerage currently has a $64.00 price target on the stock.

Other equities research analysts have also recently issued research reports about the company. Barclays decreased their target price on LivaNova from $56.00 to $55.00 and set an “equal weight” rating for the company in a research note on Thursday, May 8th. Mizuho decreased their target price on LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a research note on Wednesday, February 26th. Robert W. Baird raised their target price on LivaNova from $55.00 to $61.00 and gave the stock an “outperform” rating in a research note on Thursday, May 8th. Wolfe Research cut LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday, February 26th. Finally, StockNews.com lowered LivaNova from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 8th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $59.17.

LivaNova Trading Up 0.6%

NASDAQ LIVN opened at $43.82 on Tuesday. The business has a 50 day simple moving average of $38.28 and a 200 day simple moving average of $44.96. LivaNova has a one year low of $32.48 and a one year high of $63.57. The stock has a market capitalization of $2.39 billion, a P/E ratio of 104.33 and a beta of 0.84. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. Russell Investments Group Ltd. lifted its holdings in shares of LivaNova by 17.1% in the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock valued at $70,000 after purchasing an additional 219 shares in the last quarter. Summit Investment Advisors Inc. lifted its holdings in shares of LivaNova by 1.7% in the fourth quarter. Summit Investment Advisors Inc. now owns 16,846 shares of the company’s stock valued at $780,000 after purchasing an additional 289 shares in the last quarter. Central Pacific Bank Trust Division lifted its holdings in shares of LivaNova by 7.0% in the first quarter. Central Pacific Bank Trust Division now owns 4,407 shares of the company’s stock valued at $173,000 after purchasing an additional 290 shares in the last quarter. CWM LLC lifted its holdings in shares of LivaNova by 52.3% in the first quarter. CWM LLC now owns 871 shares of the company’s stock valued at $34,000 after purchasing an additional 299 shares in the last quarter. Finally, Xponance Inc. lifted its holdings in shares of LivaNova by 6.1% in the fourth quarter. Xponance Inc. now owns 7,762 shares of the company’s stock valued at $359,000 after purchasing an additional 445 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.